Abiraterone - CAS 154229-19-3
Not Intended for Therapeutic Use. For research use only.
Product Name:
Catalog Number:
(3beta)-17-(3-pyridinyl)-androsta-5,16-dien-3-ol; 17-(3-Pyridyl)androsta-5,16-dien-3beta-ol; CB 7598; CB-7598
CAS Number:
Abiraterone blocks the synthesis of androgens by inhibiting CYP17A1. It is used to treat metastatic, castration-resistant prostate cancer.
Molecular Weight:
Molecular Formula:
Canonical SMILES:
Cytochrome P450
Catalog Number Size Price Stock Quantity
B0084-059670 5 g $198 In stock
Bulk Inquiry
Chemical Structure
CAS 154229-19-3 Abiraterone

Related Cytochrome P450 Products

CAS 566939-85-3 Orteronel

(CAS: 566939-85-3)

Orterone (TAK-700) is an orally bioavailable non-steroidal androgen synthesis inhibitor of steroid 17alpha-monooxygenase (17,20 lyase) with potential antiandrog...

CAS 10236-47-2 Naringin

(CAS: 10236-47-2)

Naringin inhibits hepatic P-glycoprotein (P-gp) and some drug-metabolizing cytochrome P450 enzymes, including CYP3A4 and CYP1A2, which may result in drug-drug i...

CAS 117620-77-6 3-Cyano-7-ethoxycoumarin

(CAS: 117620-77-6)

3-Cyano-7-ethoxycoumarin, a kind of fluorogenic coumarin ether, is a fluorescent p450 substrate and used to confirm the effect of sorts of CYP450 enzymes.

VT-464 racemate
(CAS: 1375603-36-3)

The racemate form of VT-464, a non-steroidal compound, has been found to lead to the reduction of androgen through acting as a human CYP17 lyase inhibitor. IC50...

CAS 120511-73-1 Anastrozole

(CAS: 120511-73-1)

Anastrozole is an aromatase inhibitor that acts via binding competitively to the hem group of the CYP unit of the enzyme thereby reducing estrogen biosynthesis ...

CAS 54-36-4 Metyrapone

(CAS: 54-36-4)

Metyrapone acts as a glucocorticoid synthesis inhibitor, blocks cortisol synthesis by inhibiting steroid 11β-hydroxylase in adrenal cortex (IC50 = 7.8 μM).

CAS 115575-11-6 Liarozole

(CAS: 115575-11-6)

This active molecular has a potential antineoplastic activity. As a retinoic acid metabolism blocking agent (RAMBA), liarozole inhibits P450-dependent ATRA-4-hy...

(CAS: 1065506-69-5)

Dafadine-A, the first identified chemical inhibitor of DAF-9, could restrain the dauer formation, developmental timing and longevity in the nematodeCaenorhabdit...

(CAS: 1610537-15-9)

VT-464, also called as Seviteronel, is an oral, non-steroidal, lyase-selective CYP17 inhibitor to reach Phase II clinical trials in Breast cancer in USA (PO). i...

CAS 851983-85-2 Galeterone

(CAS: 851983-85-2)

Galeterone (TOK-001 or VN/124-1) is a novel antiandrogen under development by Tokai Pharmaceuticals for the treatment of prostate cancer. It possesses a unique ...

CAS 870093-23-5 Talarozole

(CAS: 870093-23-5)

Talarozole, a retinoic acid metabolism blocking agent (RAMBA), is a potent and selective inhibitor of cytochrome P450 26 to treat dermatalogical diseases includ...

(CAS: 1260006-20-9)

CFG920 is a Steroid 17-alpha-hydroxylase inhibitor originated by Novartis. It has potential antiandrogen and antineoplastic activities. It may inhibit cell prol...

(CAS: 1370001-71-0)

BMS-351 is a selective and nonsteroidal CYP17A1 lyase inhibitor with good selectivity over steroidogenic CYPs 21A2 and 11B1. BMS-351 has become a preclinical ca...

VT-464 R enantiomer
(CAS: 1375603-38-5)

The R-enantiomer form of VT-464, a non-steroidal compound, has been found to lead to the reduction of androgen through acting as a human CYP17 lyase inhibitor.

CAS 24144-92-1 TMS

(CAS: 24144-92-1)

TMS is a selective, competitive inhibitor of cytochrome P450 1B1 which has a very high degree of selectivity for P450 1B1 versus both P450 1A1 (>50-fold) and P4...

CAS 95-25-0 Chlorzoxazone

(CAS: 95-25-0)

Chlorzoxazone is a muscle-relaxing drug, and a probe for human liver cytochrome P-450IIE1.

CAS 154229-18-2 Abiraterone Acetate

Abiraterone Acetate
(CAS: 154229-18-2)

The acetate form of abiraterone, which blocks the synthesis of androgens by inhibiting CYP17A1.

CAS 154229-19-3 Abiraterone

(CAS: 154229-19-3)

Abiraterone blocks the synthesis of androgens by inhibiting CYP17A1. It is used to treat metastatic, castration-resistant prostate cancer.

CAS 56-54-2 Conquinine

(CAS: 56-54-2)

Conquinine is a Cytochrome P450 2D6 inhibitor. It is a dextrorotatory stereoisomer of quinine extracted from the bark of the Cinchona tree and similar plant spe...

(CAS: 854601-70-0)

Naloxegol is a CYP3A4 enzyme inhibitor. It is also a peripherally-selective opioid antagonist. It is used as the treatment of opioid-induced constipation. lt is...

Reference Reading

1. Inhibitors of enzymes of androgen biosynthesis: cytochrome P45017α and 5α-steroid reductase
Michael Jarman, H. John Smith, Paul J. Nicholls and Claire Simons. Natural Product Reports, 1998
In fact, the 3-pyridyl steroid 95 (abiraterone), was substantially more potent (Table 14) than its 2-pyridyl counterpart 96 whereas the 4-pyridyl derivative 97 was as predicted the least potent. Structural variations in rings A–C of the steroid skeleton were widely tolerated e.g. compounds 98–102. However, reduction of the △-bond led to ca. 10-fold lower inhibition, cf. 95 and 103.
2. Highly sensitive ultra-performance liquid chromatography–tandem mass spectrometry method for the determination of abiraterone in human plasma
Tanveer A. Wani*. Anal. Methods, 2013, 5, 3693–3699
Few liquid chromatography–mass spectrometry (LC–MS) methods have been reported for the analysis of ABR. These methods include a stability indicating assay to monitor ABR, and its potential degradation products besides this, two reports were found describing the determination of the ABR in biological samples (plasma). The first one employed LC–MS using single ion monitoring with a limit of quantitation of 5 nM. This method had a disadvantage of high separation time and low sensitivity. The second method included the determination of ABR by high-performance liquid chromatography–tandem mass spectrometry (HPLC–MS/MS) with a limit of quantitation of 0.20 ng mL-1.
3. Recent discoveries and developments of androgen receptor based therapy for prostate cancer
R. Elancheran, V. L. Maruthanila, M. Ramanathan, S. Kabilan, R. Devi, A. Kunnumakarae and Jibon Kotoky*. Med. Chem. Commun.,2015, 6,746–768
Abiraterone (4a), an inhibitor of CYP17 (17α-hydroxylase/C17,20-lyase), is a drug used in combination with prednisone in metastatic castration-resistant prostate cancer. It is formulated as the prodrug, abiraterone acetate. Abiraterone acetate (4b) is the active ingredient of ZYTIGA, which is the acetyl ester of abiraterone. It blocks androgen production at three sources; the testes, the adrenal glands, as well as from the tumor itself. This medication is classified as an “adrenal inhibitor”. TAK 700 (3p) is a potent, orally bioavailable and highly selective androgen synthesis inhibitor of 17, 20-lyase (CYP17A1) with IC50 values of 19 nM and 48 nM for humans and rats, respectively. It was selected for evaluation in patients in phase III clinical trials for the potential treatment of prostate cancer.
4. Anticancer steroids: linking natural and semi-synthetic compounds
Jorge A. R. Salvador,* M. Luisa Sa e Melo*. Nat. Prod. Rep., 2013, 30, 324–374
The Schneider group prepared a series of 17b-dihydrooxazinyl, oxazolidonyl and oxazolinyl steroids as presumed inhibitors of 17a-hydroxylase-C17, 20-lyase. In this group of compounds, 17β-dihydrooxazinyl derivatives did not display efficient rat testicular C17,20-lyase inhibition, however, several steroids in the oxazolidonyl and oxazolinyl series (e.g. compounds 58–60, Fig. 11) have IC50 values close to that of ketoconazole 42 and abiraterone 49.